Negative Pressure Wound Therapy in Cesarean Section (NPWTCS)

Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean

The investigators propose a prospective, randomized trial evaluating the use of negative pressure wound therapy (NPWT) with high risk obstetrical patients. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators aim to look at all wound complications such as infection and disruption and will be using Prevena incision management system for our NPWT device .

Study Overview

Status

Completed

Detailed Description

This will be a prospective, randomized, controlled trial of pregnant women who present for prenatal care at Parkland Health and Hospital System. The participants will be limited to women undergoing a cesarean section who are high risk for wound complications: all patients with a BMI > 40 undergoing cesarean section.

The primary outcome will be wound complication defined as wound disruption or wound infection. A wound disruption will be defined as the partial or complete opening of the deep subcutaneous space, not to include superficial skin separation. Underlying causes will include seroma, hematoma, abscess, and facial dehiscence. Wound infection will be defined as a physician diagnosis of wound infection with erythema and warmth extending beyond the immediate area adjacent to the incision and requiring treatment with antibiotics.

All patients with a BMI > 40 undergoing scheduled cesarean section and patients with a BMI >40 who are admitted in labor will be approached to participate in the study. If patients meeting this criteria undergo cesarean section, they will be randomized to negative pressure wound therapy or a standard dressing. All labor treatment, pre-operative antibiotics, surgical technique, and post-operative care will not differ from current standard of care. All patients randomized will be included in the study.

All study participants will have the thickness of their subcutaneous tissue measured with a sterile ruler. Patients randomized to NPWT will have a negative pressure wound therapy system placed over her incision per the manufacturer's protocol. All patients randomized to standard dressing will have the customary dressing of gauze and surgical tape placed over her incision.

The investigators will be utilizing a single use negative pressure wound therapy system for the study. Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use.

All randomized patients will undergo an examination of their incision by a research physician or nurse prior to discharge. The NPWT will be removed prior to discharge or on post-operative day seven, whichever comes first. All postpartum patients who undergo a cesarean delivery are inpatients until at least post-operative day three and will continue use of NPWT until day of discharge. In patients randomized to a standard dressing, the dressing will be removed prior to discharge per current standard of care.

All randomized patients will also undergo a 2 week post-operative incisional examination by a research physician or nurse at the obstetrical complications clinic. Patients will be followed until 30 days postpartum for any wound complications to include wound infection (superficial and deep), readmission to the hospital, re-operation for wound complications, hematoma, seroma, dehiscence, superficial infection requiring antibiotics, or additional clinical evaluations for wound care in the emergency room or clinic setting. A research physician or nurse will contact each after at least 30 days post-operative to confirm the patients' status and ensure no evaluations, admissions, or interventions were done at outside facilities.

Subjects will exit the study if they are unable to complete the post-operative visit or withdrawal consent for participation.

Study Type

Interventional

Enrollment (Actual)

441

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Dallas, Texas, United States, 75235
        • Parkland Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years to 64 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Pregnant women with BMI > 40 undergoing a cesarean delivery at Parkland Health and Hospital System.

Exclusion Criteria:

  • Any patient not meeting inclusion criteria will be deemed ineligible.
  • All HIV positive patients will be excluded due to the increased risk of infectious complications in these patients.
  • Although patients on anticoagulants can use NPWT, they will be excluded as there may be an increased risk of bleeding in these patients.
  • according to the wound therapy manufacturer's instructions patients with:

    • fragile skin
    • allergy to silver or acrylic adhesives
    • a malignancy in the wound bed or margins of the wound bed
    • non-enteric and unexplored fistulas
    • necrotic tissue with eschar present
    • exposed arteries, veins, nerves or organs, anastomotic sites, or surgical suction are not candidates for usage of the device.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Negative Pressure Wound Therapy
After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
Other Names:
  • Prevena
No Intervention: Standard dressing
After standard cesarean section completed patients will have standard dressing placed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Wound Complication
Time Frame: Day of surgery to 30 days postoperative
Number of Patients with Wound infection complications: hematoma, seroma, dehiscence, or Surgical Site Infection.
Day of surgery to 30 days postoperative
Number of Participants With Classification of Wound Morbidity
Time Frame: Day of Surgery to 30 days postoperative
Listing of different types of wound morbidity in the 2 cohorts: dehiscence, cellulitis, superficial SSI, deep SSI, organ space SSI
Day of Surgery to 30 days postoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of Postoperative Stay
Time Frame: Length of Postoperative Stay
Number of Days in Hospital after Initial Surgery
Length of Postoperative Stay
Length of Stay After Readmission
Time Frame: After dismissal and readmitted within 30 days for wound morbidity
Number of days in hospital after readmission for wound morbidity
After dismissal and readmitted within 30 days for wound morbidity
Number of Patients With Emergency Room Visits After Discharge
Time Frame: Day of surgery to 30 days postoperative
Number of emergency room visits made after initial discharge by the study (icNPT) and comparison groups.
Day of surgery to 30 days postoperative
Number of Patients With Number of Clinic Visits
Time Frame: Day of surgery to 30 days postoperative
Number of clinic visits made by patients after surgery concerning wound morbidity per patient
Day of surgery to 30 days postoperative
Number of Participants With Morbid Outcomes After Delivery
Time Frame: Day of Surgery to 30 days postoperative
Day of Surgery to 30 days postoperative
Number of Participants With Scheduled and Unscheduled Cesarean Section
Time Frame: Day of Surgery to 30 days postoperative
Cochran Mantel-Hanzel measures used to compare interactions between scheduled and unscheduled cesarean sections stratified by icNPT and standard dressing, for wound morbidity
Day of Surgery to 30 days postoperative
Number of Participants With Pfannenstiel Versus Midline Abdominal Incisions for Cesarian Section
Time Frame: Day of Surgery to 30 days postoperative
Cochran-Mantel-Haenzel test for interactions between pfannenstiel and midline abdominal incisions stratified by icNPT vs Standard dressing, for wound morbidity
Day of Surgery to 30 days postoperative
Number of Patients With Ruptured and Unruptured Membranes Prior to Cesarean Section
Time Frame: Day of Surgery to 30 days postoperative
Cochran-Mantel-Haenzel measure used to compare interaction in icNPT and Standard dressing stratified by Ruptured vs Unruptured membranes
Day of Surgery to 30 days postoperative
Number of Patients in Labor Versus no Labor Prior to Cesarean Section
Time Frame: Day of Surgery to 30 days postoperative
Cochran-Mantel-Haenzel measure used to compare interaction in icNPT and Standard dressing stratified by patients in labor and patients not in labor
Day of Surgery to 30 days postoperative
Number of Patients With Hypertension Versus no Hypertension
Time Frame: Day of Surgery to 30 days postoperative
Cochran-Mantel-Haenzel measure used to compare interaction between patients with hypertension versus no hypertension stratified by icNPT versus standard dressing, in wound morbidity
Day of Surgery to 30 days postoperative
Number of Patients With Insulin Requiring Diabetes Versus no Insulin Requiring Diabetes
Time Frame: Day of Surgery to 30 days postoperative
Cochran-Mantel-Haenzel measure used to compare interaction in icNPT and Standard wound dressings stratified by women with insulin requiring diabetes and no insulin requiring Diabetes.
Day of Surgery to 30 days postoperative
Number of Patients With Chorioamnionitis Versus no Chorioamnionitis
Time Frame: Day of Surgery to 30 days postoperative
Cochran-Mantel-Haenzel measure used to estimate interaction between chorioamnionitis and no chorioamnionitis stratified by icNPT and standard dressing, for wound morbidity
Day of Surgery to 30 days postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

3M

Investigators

  • Principal Investigator: Scott Roberts, MD, UT southwestern Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2015

Primary Completion (Actual)

August 30, 2016

Study Completion (Actual)

October 21, 2016

Study Registration Dates

First Submitted

October 6, 2014

First Submitted That Met QC Criteria

November 7, 2014

First Posted (Estimate)

November 13, 2014

Study Record Updates

Last Update Posted (Actual)

July 2, 2018

Last Update Submitted That Met QC Criteria

May 31, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STU 042014-047

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Wound Complications

Clinical Trials on Negative pressure wound therapy

Subscribe